Cwm LLC Has $361,000 Position in Qiagen N.V. $QGEN

Cwm LLC boosted its stake in shares of Qiagen N.V. (NYSE:QGEN) by 153.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,521 shares of the company’s stock after acquiring an additional 4,556 shares during the quarter. Cwm LLC’s holdings in Qiagen were worth $361,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. SVB Wealth LLC acquired a new position in Qiagen during the first quarter worth $31,000. Farther Finance Advisors LLC raised its stake in Qiagen by 400.5% during the second quarter. Farther Finance Advisors LLC now owns 1,061 shares of the company’s stock worth $51,000 after acquiring an additional 849 shares in the last quarter. Hilltop National Bank acquired a new stake in shares of Qiagen in the second quarter valued at $66,000. ANTIPODES PARTNERS Ltd acquired a new stake in shares of Qiagen in the first quarter valued at $94,000. Finally, GAMMA Investing LLC increased its stake in shares of Qiagen by 93.9% in the first quarter. GAMMA Investing LLC now owns 2,943 shares of the company’s stock valued at $118,000 after buying an additional 1,425 shares in the last quarter. 70.00% of the stock is currently owned by institutional investors and hedge funds.

Qiagen Price Performance

Qiagen stock opened at $49.37 on Friday. The firm has a market capitalization of $10.97 billion, a P/E ratio of 29.17, a PEG ratio of 2.59 and a beta of 0.66. Qiagen N.V. has a 1 year low of $37.63 and a 1 year high of $51.88. The business has a 50-day moving average of $47.00 and a 200-day moving average of $46.15. The company has a current ratio of 1.61, a quick ratio of 1.35 and a debt-to-equity ratio of 0.25.

Qiagen (NYSE:QGEN) last posted its earnings results on Tuesday, August 5th. The company reported $0.60 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.60. The company had revenue of $533.54 million during the quarter, compared to analyst estimates of $523.97 million. Qiagen had a return on equity of 14.77% and a net margin of 18.30%.The company’s revenue for the quarter was up 7.7% compared to the same quarter last year. During the same period in the previous year, the company earned $0.55 EPS. Qiagen has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. On average, equities analysts anticipate that Qiagen N.V. will post 2.26 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on QGEN shares. Weiss Ratings restated a “hold (c+)” rating on shares of Qiagen in a research note on Saturday. Barclays set a $53.00 target price on Qiagen and gave the company an “overweight” rating in a research note on Thursday, October 2nd. UBS Group raised their target price on Qiagen from $48.00 to $50.00 and gave the company a “neutral” rating in a research note on Thursday, August 7th. Cowen restated a “hold” rating on shares of Qiagen in a research note on Thursday, August 7th. Finally, Wall Street Zen lowered Qiagen from a “buy” rating to a “hold” rating in a research note on Saturday, October 11th. Three equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $49.69.

Qiagen Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.